HighMark Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

HighMark Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$384	Hold	41	–	–	﹤0.01%	527
2026 Q1	$384	Hold	41	–	–	﹤0.01%	516
2025 Q4	$333	Hold	41	–	–	﹤0.01%	551
2025 Q3	$519	Hold	41	–	–	﹤0.01%	555
2025 Q2	$283	Hold	41	–	–	﹤0.01%	577
2025 Q1	$218	Hold	41	–	–	﹤0.01%	548
2024 Q4	$484	Hold	41	–	–	﹤0.01%	532
2024 Q3	$846	Hold	41	–	–	﹤0.01%	523
2024 Q2	$1.85K	Hold	41	–	–	﹤0.01%	476
2024 Q1	$1.61K	Hold	41	–	–	﹤0.01%	487
2023 Q4	$248	Hold	41	–	–	﹤0.01%	551
2023 Q3	$276	Hold	41	–	–	﹤0.01%	540
2023 Q2	$321	Hold	41	–	–	﹤0.01%	532
2023 Q1	$298	Sell	41 -108	-72%	-$472	﹤0.01%	573
2022 Q4	$495	Hold	149	–	–	﹤0.01%	501
2022 Q3	$1K	Hold	149	–	–	﹤0.01%	467
2022 Q2	$1K	Hold	149	–	–	﹤0.01%	468
2022 Q1	$2K	Hold	149	–	–	﹤0.01%	438
2021 Q4	$3K	Hold	149	–	–	﹤0.01%	397
2021 Q3	$5K	Hold	149	–	–	﹤0.01%	353
2021 Q2	$8K	Hold	149	–	–	0.01%	284
2021 Q1	$9K	Sell	149 -184	-55%	-$12.1K	0.01%	242
2020 Q4	$12K	Hold	333	–	–	0.01%	200
2020 Q3	$18K	Hold	333	–	–	0.02%	174
2020 Q2	$84K	Hold	333	–	–	0.09%	59
2020 Q1	$52K	Buy	+333	New	+$56.3K	0.06%	64

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

HighMark Wealth Management's CRBP Position: Q2 2026 in Review

HighMark Wealth Management held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 41 shares worth $384. The position accounts for ﹤0.01% of the portfolio, ranked #527.

HighMark Wealth Management first reported a position in CRBP in Q1 2020 and has held it in 26 quarters since. The position peaked at $84K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

HighMark Wealth Management held 41 shares of Corbus Pharmaceuticals worth $384 as of Q2 2026.
HighMark Wealth Management left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
Corbus Pharmaceuticals made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #527 holding.
HighMark Wealth Management first reported a position in Corbus Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
HighMark Wealth Management's Corbus Pharmaceuticals position peaked at $84K in Q2 2020.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.